Pharmaceutical company Cempra (NASDAQ: CEMP) creates antibiotics to treat bacterial infections. The company produces Solithromycin, a treatment for community-acquired bacterial pneumonia that is now …
In a research report sent to investors today, Needham analyst Alan Carr maintained a Buy rating on Cempra (NASDAQ:CEMP) and raised his price target …
